| Company Name: | Agenus, Inc. | | Ticker Symbol: | AGEN | | | WWW Address: | www.antigenics.com |
| CEO: | Dr. Garo H Armen PhD | | No. of Employees: | 53 |
| Common Issue Type: | CS | | Business Description: | Agenus, Inc. is a biotechnology company, which is developing and commercializing technologies to treat cancers and infectious diseases, based on immunological approaches.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.15 |  -0.1 | 3.31 | 4.55 | 4.24 | 4.29 | 4.16 | 102553 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 117.5 | 28.3 | 2.01 | -0.51 | 0.00 | 0.0 | 0.0 | 5.99 - 3.37 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.25 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 117.5 | mil |
| Latest Shares Outstanding | 28.3 | mil |
| Earnings pS (EPS) | -0.51 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 301,146 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 26.0 | mil |
| Float as % of Shares Outstanding | 93.2 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 310.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 282.60 | % |
| Gross Profit Margin | 75.1 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -68.3 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -217.7 | % |
| Current Ratio | 3.2 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 459.0 | % |
| Working Capital pS | 0.44 | $ |
| Cash pS | 0.61 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -1.09 | $ |
| Cash Flow pS | -0.69 | $ |
| Free Cash Flow pS | -0.54 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -3.90 | |
| Price/Cash Flow | -6.2 | |
| Price/Free Cash Flow | -7.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.2 | 95 | 1,769 | 6,368 |
| 4 Weeks | 5.40 | 3.95 | 4.30 | -1.2 | 92 | 3,147 | 62,938 |
| 13 Weeks | 5.40 | 3.70 | 4.36 | -2.5 | 89 | 1,593 | 100,356 |
| 26 Weeks | 5.40 | 3.37 | 3.52 | 20.7 | 99 | 1,215 | 150,649 |
| 52 Weeks | 5.99 | 3.37 | 5.45 | -22.0 | 61 | 1,364 | 339,569 |
| YTD | 5.40 | 3.70 | - | 3.7 | 89 | 1,362 | 129,396 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.30 | 4.31 | 4.30 | 4.22 | 4.35 | 2.01 | 2.29 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 19.84 | 26.8 | 37.79 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 20.41 | NA | -29.14 |
| R&D | -14.54 | NA | -12.40 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -91.7 | -91.7 | 479.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -100.0 | -100.0 | 0.0 |
| EPS $ | -0.64 | -0.64 | 0.70 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 61.19 |
| Current Ratio | 4.7 |
| Quick Ratio (Acid Test) | 4.6 |
| Liquidity Ratio (Cash) | 4.46 |
| Receivables Turnover | 57.8 |
| Average Collection Period | 6 |
| Working Capital/Equity | -76.8 |
| Working Capital pS | 0.72 |
| Cash-Flow pS | -0.43 |
| Free Cash-Flow pS | 0.01 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.13 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 179.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 378.7 |
| LT Debt/Total Liabilities | 68.3 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 19.43 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 12.52 |
| Tobin's Q Ratio | 4.13 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -22.42 |
| Enterprise Value (EV)/Free Cash Flow | 362.93 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -3.90 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -6.2 |
| Price/Free Cash Flow Ratio - LTM | -7.9 |
| Price/Sales Ratio | 32.56 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 1.45 |
| Current Liabilities pS | 0.20 |
| Tangible Book Value pS - LTM | -1.09 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.44 |
| Cash pS - LTM | 0.61 |
| Cash Flow pS - LTM | -0.69 |
| Free Cash Flow pS - LTM | -0.54 |
| Earnings pS (EPS) | -0.51 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 1.98 |
| Free Cash Flow Margin 5YEAR AVG | -593.94 |
| Net Profit Margin | -71.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.69 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.27 |
| Return on Capital Invested (ROCI) | -90.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -34.9 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | -38.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | -21.9 |
| Gross Profit Margin | 75.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | -81.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 22 |
| Revenue per Employee | 301,146 |
| Net Income per Employee | -213,675 |
| Average Collection Period | 12 |
| Receivables Turnover | 57.8 |
| Day's Inventory Turnover Ratio | 10 |
| Inventory Turnover | 37.2 |
| Inventory/Sales | 0.1 |
| Accounts Payble/Sales | 3.98 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 0.90 |
| Fixed Assets Turnover | 2.46 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 0.74 |
| Revenue per $ Plant | 6.12 |
| Revenue per $ Common Equity | -0.69 |
| Revenue per $ Capital Invested | 1.27 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 71.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 243.5 |
| Research & Devlopment (R&D) as % of Revenue | 66.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 66.2 |
|
|  
|
| |
 |  |
